The role of telavancin in the treatment of MRSA infections in hospital.

abstract：:Introduction: The conventional management of most patients with metastatic urothelial carcinoma (UC) is platinum-based chemotherapy followed by immunotherapy. Erdafitinib is an option in post-platinum patients with activating mutations in fibroblast growth factor receptor (FGFR)-3 and -2. Salvage therapy with taxanes ...

journal_title：Expert opinion on investigational drugs

authors： McGregor BA,Sonpavde G

更新日期：2019-10-01 00:00:00

abstract：:Psoriasis is a common skin disease which is characterised by the proliferation and abnormal differentiation of keratinocytes, coupled with complex immune disturbances. The beneficial effects of vitamin D derivatives in this disease are due to their capacity to inhibit proliferation, their ability to induce normal diff...

journal_title：Expert opinion on investigational drugs

authors： Guilhou JJ

更新日期：1998-01-01 00:00:00

abstract：:PDE3 cyclic nucleotide phosphodiesterases are important in cyclic AMP (cAMP) and possibly cyclic GMP-mediated signalling in cardiac and vascular smooth muscle myocytes. Drugs that inhibit these enzymes have inotropic and vasodilatory actions that have proven useful in the short-term treatment of contractile failure an...

journal_title：Expert opinion on investigational drugs

authors： Movsesian MA,Alharethi R

更新日期：2002-11-01 00:00:00

abstract：:Interstitial cystitis (IC) is a painful, sterile, disorder of the urinary bladder characterised by urgency, frequency, nocturia and pain. IC occurs primarily in women but also in men with recent findings indicating that chronic, abacterial prostatitis may be a variant of this condition. The prevalence of IC has ranged...

journal_title：Expert opinion on investigational drugs

authors： Theoharides TC,Sant GR

更新日期：2001-03-01 00:00:00

abstract：:With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B-cell non-Hodgkin's-lymphomas (NHL) has gained momentum. Since the first description of the CD20 mAb and its use in a single patient, it has taken more than 20 years to implement this in current t...

journal_title：Expert opinion on investigational drugs

authors： Schultze JL

更新日期：1999-12-01 00:00:00

abstract：:The management of acute myocardial infarction (AMI) has changed dramatically over the last two decades, with the addition of fibrinolytic agents and primary coronary intervention (PCI). The more recent development of the glycoprotein (GP) IIb/IIIa antagonists, a new class of potent antiplatelet drugs, has the potentia...

journal_title：Expert opinion on investigational drugs

authors： Ferguson JJ,Vaisman D

更新日期：2001-11-01 00:00:00

abstract：INTRODUCTION:Epithelial ovarian cancer (EOC) is the leading cause of gynaecologic cancer death. Although in some cases initial treatment is effective, most of the women diagnosed with EOC will probably need medical treatment for their disease. There is a critical need to develop effective new strategies for the managem...

journal_title：Expert opinion on investigational drugs

authors： Morotti M,Becker CM,Menada MV,Ferrero S

更新日期：2013-10-01 00:00:00

abstract：:Neuroimmunophilin ligands are a class of compounds that hold great promise for the treatment of nerve injuries and neurological disease. In contrast to neurotrophins (e.g., nerve growth factor), these compounds readily cross the blood-brain barrier, being orally effective in a variety of animal models of ischaemia, tr...

journal_title：Expert opinion on investigational drugs

authors： Gold BG

更新日期：2000-10-01 00:00:00

abstract：:Introduction: Therapeutic oligonucleotides have emerged as a promising new class of drug that could silence undruggable targets; they can potentially treat metabolic liver diseases such as nonalcoholic fatty liver disease (NAFLD), hereditary hemochromatosis and alpha 1 antitrypsin deficiency. Areas covered: This artic...

journal_title：Expert opinion on investigational drugs

authors： Alkhouri N,Gawrieh S

更新日期：2021-01-29 00:00:00

abstract：BACKGROUND:Chronic hepatitis C virus (HCV) infection is a worldwide health problem. Response rates to current standard of treatment (pegylated IFNs and ribavirin) are low in patients with the prevailing genotype 1. OBJECTIVE:To review papers published or presented at recent international meetings showing the results o...

journal_title：Expert opinion on investigational drugs

authors： Vento S,Cainelli F,Temesgen Z

更新日期：2008-11-01 00:00:00

abstract：INTRODUCTION:GLP-1 receptor agonists have been shown to be effective in the treatment of type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, exenatide, was approved in the mid-2000s, other agents with longer durations of action (that do not require twice-daily dosing) are now being developed. In...

journal_title：Expert opinion on investigational drugs

authors： Garber AJ

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Acute decompensated heart failure (ADHF) is associated with increased hospitalization rates and high in-hospital mortality, and has emerged as a major public health problem over the past decade. In recent years, several new drugs and therapeutic approaches have failed to reduce short- and long-term morbidity...

journal_title：Expert opinion on investigational drugs

authors： Triposkiadis F,Parissis JT,Starling RC,Skoularigis J,Louridas G

更新日期：2009-06-01 00:00:00

abstract：:The utility of transgenic animal bioreactors for the production of complex therapeutic proteins is based on lower production costs, higher production capacities and safer, pathogen free products. Until gene therapy becomes broadly efficacious, transgenic-derived therapeutics are the most attractive alternative for pro...

journal_title：Expert opinion on investigational drugs

authors： Van Cott KE,Velander WH

更新日期：1998-10-01 00:00:00

abstract：BACKGROUND:Armodafinil is a wake-promoting agent developed by Cephalon that was approved in mid-2007 for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder. It is the R-enantiomer of the compound modafinil. Like modafinil, the mechanism of action for armoda...

journal_title：Expert opinion on investigational drugs

authors： Lankford DA

更新日期：2008-04-01 00:00:00

abstract：INTRODUCTION:In the treatment of advanced/metastatic head and neck cancer (HNC), resistance to chemotherapy and to anti-EGFR agents remains a major issue, and new molecular drugs are eagerly awaited. Over the last decade, knowledge of the genetic landscape of HNC has rapidly grown. However, no tailored therapeutic inte...

journal_title：Expert opinion on investigational drugs

authors： Bossi P,Alfieri S

更新日期：2016-07-01 00:00:00

abstract：:Hepatitis C virus is the most common chronic, blood-bourne infection, affecting 170 million people worldwide, approximately 3% of the global population. Of those infected with hepatitis C virus, 50 - 85% will develop chronic hepatitis C. Although hepatitis C is primarily a disease of the liver, a diagnosis is currentl...

journal_title：Expert opinion on investigational drugs

authors： Pockros PJ

更新日期：2002-04-01 00:00:00

abstract：:Growth hormone-insensitivity syndrome (GHIS) is usually caused by mutations in the growth hormone receptor. Recombinant IGF-I has been used to treat GHIS either alone (mecasermin) or in combination with IGF-binding protein (IGFBP)-3 (mecasermin rinfabate). IGF-I increases the growth velocity of children with IGF defic...

journal_title：Expert opinion on investigational drugs

authors： Kemp SF,Thrailkill KM

更新日期：2006-04-01 00:00:00

abstract：:Background: We aimed to estimate population-based trends in the prevalence of coexisting type 2 diabetes (T2D) and suspected nonalcoholic fatty liver disease (NAFLD) and pioglitazone use among U.S. adults.Research design and methods: We conducted a cross-sectional analysis of the National Health and Nutrition Examinat...

journal_title：Expert opinion on investigational drugs

authors： Le P,Chaitoff A,Rothberg MB,McCullough A,Alkhouri N

更新日期：2020-02-01 00:00:00

abstract：:The role of nerve growth factor in stimulating cholinergic function, loss of which is a cardinal feature in Alzheimer's disease, has been documented for many years from preclinical animal model studies. This anabolic growth factor has been delivered into the forebrain of patients with mild Alzheimer's disease using tr...

journal_title：Expert opinion on investigational drugs

authors： Braddock M

更新日期：2005-07-01 00:00:00

abstract：INTRODUCTION:Aberrant regulation of platelet-derived growth factors (PDGFs) and their receptors (PDGFR) has been shown to be involved in many solid tumors, including breast cancer. PDGFR-α and PDGFR-β expressions were documented in breast cancer and are correlated with tumor aggressiveness and metastasis. Preclinical e...

journal_title：Expert opinion on investigational drugs

authors： Criscitiello C,Gelao L,Viale G,Esposito A,Curigliano G

更新日期：2014-05-01 00:00:00

abstract：:When the 'handle region' of the prorenin prosegment interacts with the (pro)renin receptor, the prorenin molecule partially changes the conformation to an enzymatically active state. On the other hand, the receptor triggers its own intracellular signalling pathways independent of the renin-angiotensin system (RAS). Th...

journal_title：Expert opinion on investigational drugs

authors： Ichihara A,Kaneshiro Y,Suzuki F

更新日期：2006-10-01 00:00:00

abstract：INTRODUCTION:Regorafenib (BAY 73-4506) is a novel, orally active, diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-β, FGFR-1, RET, RAF-1, BRAF and p38 MAP kinase. AREAS COVERED:This review covers the preclinical development of regorafenib as well as the pivotal Phase I studies. The safety profile of...

journal_title：Expert opinion on investigational drugs

authors： Strumberg D,Schultheis B

更新日期：2012-06-01 00:00:00

abstract：INTRODUCTION:The introduction of therapy with tumor necrosis factor antagonists (aTNF) was a cornerstone of treatment modalities in patients with ankylosing spondylitis (AS). After > 10 years of using aTNF, the introduction of aTNF therapy was a major step forward in the medical management of patients with spondyloarth...

journal_title：Expert opinion on investigational drugs

authors： Braun J,Baraliakos X,Heldmann F,Kiltz U

更新日期：2014-05-01 00:00:00

abstract：:The deposition of a platelet rich thrombus on an atherosclerotic plaque is a critical step in the development of unstable coronary syndromes. Currently available therapeutic agents such as aspirin and ticlopidine are relatively weak inhibitors of platelet aggregation. Recently, antagonists to platelet glycoprotein IIb...

journal_title：Expert opinion on investigational drugs

authors： Kumar A,Herrmann HC

更新日期：1997-09-01 00:00:00

abstract：INTRODUCTION:Peripheral arterial disease (PAD) is a manifestation, and marker of severity, of a generalized atherosclerotic process. Antiplatelet therapy is recommended to prevent cardiovascular events but much of the evidence to support this is drawn from studies on older drugs. AREAS COVERED:In this review, the auth...

journal_title：Expert opinion on investigational drugs

authors： Chong AY,So DY

更新日期：2014-12-01 00:00:00

abstract：:Of the antiarrhythmic drugs in current use, amiodarone is one of the most effective and is associated with a comparatively low risk of drug-induced pro-arrhythmia, probably due to its multiple pharmacological actions on cardiac ion channels and receptors. However, amiodarone is associated with significant extra-cardia...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA,Hancox JC

更新日期：2004-04-01 00:00:00

abstract：INTRODUCTION:Melanoma is one of the most aggressive forms of cutaneous malignancies displaying a substantial mortality rate among the various forms of skin cancers. The management of patients with advanced melanoma poses a significant challenge considering that the disease is refractory to most conventional therapies. ...

journal_title：Expert opinion on investigational drugs

authors： Bhatia S,Emdad L,Das SK,Hamed H,Dent P,Sarkar D,Fisher PB

更新日期：2014-04-01 00:00:00

abstract：BACKGROUND:Fenofibrate is the most widely used fibrate. Its efficacy and tolerability in the treatment of hypertriglyceridaemia and combined hyperlipidaemia have been demonstrated in several clinical trials. OBJECTIVE:To review the pharmacology, lipid-lowering and extra-lipid effects of fenofibrate and to preview ABT-...

journal_title：Expert opinion on investigational drugs

authors： Filippatos T,Milionis HJ

更新日期：2008-10-01 00:00:00

abstract：BACKGROUND:Clusterin is a stress-induced cytoprotective chaperone protein, regulated by HSF1, and functions similarly to a small heat-shock protein. Clusterin is expressed in a variety of cancers and associated with broad-spectrum treatment resistance. Custirsen (OGX-011) is a 2'-methoxyethyl modified phosphorothioate ...

journal_title：Expert opinion on investigational drugs

authors： Chi KN,Zoubeidi A,Gleave ME

更新日期：2008-12-01 00:00:00

abstract：INTRODUCTION:Posttraumatic stress disorder (PTSD) is a prevalent, chronic and disabling anxiety disorder that may develop following exposure to a traumatic event. There is currently no effective pharmacotherapy for PTSD and therefore the discovery of novel, evidence-based treatments is particularly important. This revi...

journal_title：Expert opinion on investigational drugs

authors： Ragen BJ,Seidel J,Chollak C,Pietrzak RH,Neumeister A

更新日期：2015-05-01 00:00:00